Trial · NCT06261840
Refining Treatment Options for Trichomonas Vaginalis Infection: A Comparative Analysis of Metronidazole and Secnidazole
NCT06261840, Phase 4, Recruiting, Tulane University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Refining Treatment Options for Trichomonas Vaginalis Infection: A Comparative Analysis of Metronidazole and Secnidazole. Trials, record NCT06261840. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06261840
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Refining Treatment Options for Trichomonas Vaginalis Infection: A Comparative Analysis of Metronidazole and Secnidazole
- NCT number
- NCT06261840
- Status
- Recruiting
- Phases
- Phase 4
- Enrollment
- 1,200 participants, estimated
- Lead sponsor
- Tulane University
- Conditions
- Trichomonas Vaginitis, Bacterial Vaginitis
- Interventions
- Metronidazole 500 mg, Secnidazole 2000 MG
- First posted
- 2024-02-15
- Last updated
- 2026-05-06
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Treatment, as Measured by the Number of Participants that are Cured of Trichomonas Vaginalis at one month test of cure. | A TOC visit will be scheduled 4 weeks (+- 1 week) after post completion of treatment | A repeat T. vaginalis NAAT test will be completed at the test of cure (TOC) visit |
| Secondary | To examine if BV co-infection interferes with T. vaginalis treatment | From enrollment to completion of one-month test of cure for those who test BV positive at baseline. | Of those who test positive for BV via BV OSOM at baseline, those who re-test positive via BV OSOM at one-month test-of-cure will be compared by treatment arm. |
| Secondary | To examine if oral single-dose secnidazole is superior to oral multi-dose metronidazole for the treatment of BV. | From baseline visit to one-month test of cure visit | We will conduct a secondary analysis to compare the effectiveness of oral single-dose secnidazole versus oral multi-dose metronidazole among women enrolled in the trial with a diagnosis of BV at baseline. Those who test positive for BV via BV OSOM at baseline will be re-tested and BV positivity at one-month will be compared by treatment arm. |
| Secondary | A comparison of participant preferences for the test-of-cure (TOC) visit (in clinic versus telemedicine) as captured on baseline survey. | From baseline visit to one-month test of cure visit | Participants will be asked their preference for an in person one-month test of cure visit that is in person versus telehealth. |
| Secondary | A comparison of TV NAAT confirmatory test results to determine the percentage who spontaneously clear the infection without medication. | at baseline, we document their prior test result (per medical records, survey or onsite testing). | Women and men who previously tested positive for T. vaginalis by nucleic acid amplification test (NAAT) will be retested by NAAT at study entry. The rate of early spontaneous resolution will be calculated. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 42031495 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06261840
GET https://conductscience.org/api/trials/v1/NCT06261840/registered